Literature DB >> 19295549

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

A Tefferi, K-H Lim, O Abdel-Wahab, T L Lasho, J Patel, M M Patnaik, C A Hanson, A Pardanani, D G Gilliland, R L Levine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19295549      PMCID： PMC4654626          DOI： 10.1038/leu.2009.59

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

Review 1.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

2.  Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.

Authors:  A Tefferi; T L Lasho; J Huang; C Finke; R A Mesa; C Y Li; W Wu; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

3.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

4.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528
  4 in total
  109 in total

Review 1.  Molecular biology of myelodysplastic syndromes.

Authors:  Alan H Shih; Ross L Levine
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms.

Authors:  Thomas Ernst; Andrew Chase; Katerina Zoi; Katherine Waghorn; Claire Hidalgo-Curtis; Joannah Score; Amy Jones; Francis Grand; Andreas Reiter; Andreas Hochhaus; Nicholas C P Cross
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 3.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

4.  Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Authors:  Hadrian Szpurka; Anna M Jankowska; Hideki Makishima; Juraj Bodo; Nelli Bejanyan; Eric D Hsi; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Leuk Res       Date:  2010-03-23       Impact factor: 3.156

5.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.

Authors:  Ramon V Tiu; Lukasz P Gondek; Christine L O'Keefe; Paul Elson; Jungwon Huh; Azim Mohamedali; Austin Kulasekararaj; Anjali S Advani; Ronald Paquette; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-02-01       Impact factor: 22.113

Review 6.  TET family proteins: new players in gliomas.

Authors:  Er-Bao Bian; Gang Zong; Yong-Sheng Xie; Xiao-Ming Meng; Cheng Huang; Jun Li; Bing Zhao
Journal:  J Neurooncol       Date:  2014-01-07       Impact factor: 4.130

7.  The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.

Authors:  Su Jung Song; Keisuke Ito; Ugo Ala; Lev Kats; Kaitlyn Webster; Su Ming Sun; Mojca Jongen-Lavrencic; Katia Manova-Todorova; Julie Teruya-Feldstein; David E Avigan; Ruud Delwel; Pier Paolo Pandolfi
Journal:  Cell Stem Cell       Date:  2013-07-03       Impact factor: 24.633

8.  FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

Authors:  Fábio Morato de Oliveira; Carlos Eduardo Miguel; Antônio Roberto Lucena-Araujo; Ana Silvia Gouvêa de Lima; Roberto Passetto Falcão; Eduardo Magalhães Rego
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

9.  Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms.

Authors:  Kebede Hussein; Omar Abdel-Wahab; Terra L Lasho; Daniel L Van Dyke; Ross L Levine; Curtis A Hanson; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

Review 10.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.